Table 4.
Disproportionality signal analysis calculated by using the information component (IC), comparing a monotherapeutical approach using each drug to all other PD-1/PD-L1/CTLA-4 agents, for 2017–2023.
| Adverse Events | Pembrolizumab | Cemiplimab | Nivolumab | Atezolizumab | Avelumab | Durvalumab | Ipilimumab |
|---|---|---|---|---|---|---|---|
| Cardiac failure | −0.37 (−0.63–0.26) |
0.91 (−0.50–3.99) |
0.12 (−0.08–0.59) |
−0.59 (−1.11–0.66) |
−0.29 (−1.43–2.26) |
−0.41 (−0.94–0.83) |
−2.45 (−4.01–0.89) |
| Atrial Fibrillation | −0.60 (−0.91–0.15) |
−0.87 (−4.65–5.33) |
−0.26 (−0.53–0.38) |
−0.20 (−0.73–1.04) |
0.37 (−0.66–2.69) |
−0.91 (−1.64–0.79) |
−0.92 (−1.95–1.40) |
| Myocardial infarction | 0.02 (−0.32–0.82) |
0.46 (−2.14–5.34) |
0.15 (−0.14–0.84) |
0.22 (−0.37–1.60) |
0.45 (−0.85–3.32) |
0.45 (−0.13–1.82) |
−1.33 (−2.89–2.01) |
| Pericardial disease | 0.14 (−0.10–0.72) |
−0.18 (−2.77–4.70) |
0.15 (−0.07–0.67) |
0.34 (−0.08–1.34) |
−1.05 (−2.81–2.64) |
−0.45 (−1.06–0.98) |
−2.42 (−4.18–1.26) |
| Myocarditis | 0.01 (−0.19–0.49) |
0.34 (−1.22–3.68) |
−0.19 (−0.38–0.27) |
−0.91 (−1.42–0.29) |
−0.04 (−0.95–2.03) |
−0.87 (−1.42–0.42) |
−0.87 (−1.62–0.87) |
| QT prolongation | −4.77 (−15.10–5.01) |
−0.46 (−10.79–9.32) |
−1.42 (−2.99–1.92) |
−3.15 (−13.47–6.64) |
−1.27 (−11.60–8.51) |
−2.96 (−13.28–6.83) |
0.23 (−2.36–5.12) |